Analysts predict that United Therapeutics Corporation (NASDAQ:UTHR) will report $430.87 million in sales for the current fiscal quarter, Zacks Investment Research reports. Six analysts have made estimates for United Therapeutics Corporation’s earnings, with the highest sales estimate coming in at $442.51 million and the lowest estimate coming in at $415.90 million. United Therapeutics Corporation posted sales of $408.20 million during the same quarter last year, which suggests a positive year-over-year growth rate of 5.6%. The company is scheduled to issue its next earnings results on Thursday, October 26th.

According to Zacks, analysts expect that United Therapeutics Corporation will report full-year sales of $430.87 million for the current fiscal year, with estimates ranging from $1.59 billion to $1.72 billion. For the next financial year, analysts expect that the company will post sales of $1.38 billion per share, with estimates ranging from $1.22 billion to $1.55 billion. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that cover United Therapeutics Corporation.

United Therapeutics Corporation (NASDAQ:UTHR) last posted its earnings results on Thursday, July 27th. The biotechnology company reported ($1.25) earnings per share for the quarter, missing analysts’ consensus estimates of $3.61 by ($4.86). United Therapeutics Corporation had a net margin of 24.18% and a return on equity of 20.96%. The business had revenue of $444.60 million during the quarter, compared to analysts’ expectations of $391.53 million. During the same period last year, the business posted $4.42 earnings per share. The company’s revenue for the quarter was up 7.8% compared to the same quarter last year.

UTHR has been the subject of several research reports. ValuEngine upgraded United Therapeutics Corporation from a “buy” rating to a “strong-buy” rating in a research report on Thursday, July 13th. BidaskClub cut United Therapeutics Corporation from a “buy” rating to a “hold” rating in a research report on Wednesday, July 19th. Zacks Investment Research cut United Therapeutics Corporation from a “hold” rating to a “sell” rating in a research report on Thursday, July 13th. Oppenheimer Holdings, Inc. reiterated a “buy” rating on shares of United Therapeutics Corporation in a research report on Friday, September 8th. Finally, UBS AG reiterated a “sell” rating and set a $106.00 price target on shares of United Therapeutics Corporation in a research report on Thursday, July 6th. Five analysts have rated the stock with a sell rating, seven have issued a hold rating and three have given a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $132.09.

United Therapeutics Corporation (UTHR) opened at 119.78 on Tuesday. United Therapeutics Corporation has a 12-month low of $110.90 and a 12-month high of $169.89. The company has a 50 day moving average of $122.99 and a 200-day moving average of $126.06. The stock has a market capitalization of $5.20 billion, a price-to-earnings ratio of 13.89 and a beta of 1.50.

ILLEGAL ACTIVITY WARNING: This story was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this story on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark legislation. The original version of this story can be read at https://www.watchlistnews.com/430-87-million-in-sales-expected-for-united-therapeutics-corporation-uthr-this-quarter/1635970.html.

In other news, CEO Martine A. Rothblatt sold 1,236 shares of the company’s stock in a transaction on Thursday, July 20th. The stock was sold at an average price of $131.62, for a total value of $162,682.32. Following the transaction, the chief executive officer now owns 1,376 shares of the company’s stock, valued at approximately $181,109.12. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Martine A. Rothblatt sold 1,247 shares of the company’s stock in a transaction on Thursday, July 27th. The shares were sold at an average price of $126.40, for a total value of $157,620.80. Following the completion of the transaction, the chief executive officer now directly owns 2,316 shares in the company, valued at approximately $292,742.40. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 18,323 shares of company stock valued at $2,312,667. 7.80% of the stock is owned by company insiders.

Several institutional investors have recently made changes to their positions in the company. HPM Partners LLC lifted its stake in shares of United Therapeutics Corporation by 0.8% in the 2nd quarter. HPM Partners LLC now owns 1,981 shares of the biotechnology company’s stock valued at $257,000 after purchasing an additional 15 shares during the last quarter. First Allied Advisory Services Inc. lifted its stake in shares of United Therapeutics Corporation by 0.4% in the 2nd quarter. First Allied Advisory Services Inc. now owns 4,579 shares of the biotechnology company’s stock valued at $598,000 after purchasing an additional 19 shares during the last quarter. Nomura Asset Management Co. Ltd. lifted its stake in shares of United Therapeutics Corporation by 0.3% in the 1st quarter. Nomura Asset Management Co. Ltd. now owns 12,646 shares of the biotechnology company’s stock valued at $1,712,000 after purchasing an additional 40 shares during the last quarter. Fisher Asset Management LLC lifted its stake in shares of United Therapeutics Corporation by 1.4% in the 2nd quarter. Fisher Asset Management LLC now owns 3,169 shares of the biotechnology company’s stock valued at $411,000 after purchasing an additional 45 shares during the last quarter. Finally, Synovus Financial Corp lifted its stake in shares of United Therapeutics Corporation by 1.2% in the 2nd quarter. Synovus Financial Corp now owns 5,639 shares of the biotechnology company’s stock valued at $731,000 after purchasing an additional 69 shares during the last quarter.

About United Therapeutics Corporation

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Get a free copy of the Zacks research report on United Therapeutics Corporation (UTHR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for United Therapeutics Corporation (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.